# KLOW Peptide Dosage: Research Context for the Four-Peptide Blend > KLOW peptide dosage as documented in the research literature — component-level doses from single-component studies, the canonical 80 mg vial composition, pharmacokinetics and the inherent blend mismatch. Not a dosing recommendation. There is no validated human dose for the KLOW blend. What exists is the canonical vial composition — 80 mg total at a 50/10/10/10 split — and the separate dose ranges from each component's single-compound research. Those are documented here. ## In plain English There is no approved or validated human dosage for KLOW peptide. The blend has never been tested in a human study — or any controlled animal study. What does exist is a canonical research-vial composition (80 mg total, split 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV) that independent compounders have converged on, and a body of single-component dose-range data from the preclinical and limited human literature for each of the four peptides. This page documents that research-context information. None of it is a dosing recommendation. The component doses are not additive into a single 'KLOW dose' — the pharmacokinetic profiles of the four peptides differ too substantially for a single co-formulated vial to maintain all four at matched exposures. ## KLOW peptide dosage The canonical research-vial composition for KLOW is an 80 mg total lyophilized vial, reconstituted with bacteriostatic water for laboratory handling. The split is: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. This is not a dose — it is the composition of one research vial as supplied. It reflects a standardized format adopted by independent compounders, not a validated research protocol. ## KLOW dosage No controlled study has tested the KLOW blend at any dose in any species. The 80 mg vial composition is a preparation specification, not a dosing recommendation derived from pharmacological research. ## KLOW peptide dosage and frequency No validated frequency or cycle-length data exists for the blend. Component-level research studies used varying schedules — once daily intraperitoneal injection in rodent tendon models for BPC-157, topical or intraperitoneal administration in the thymosin β4 wound model — and those schedules were designed around single-compound pharmacokinetics, not a co-formulation. Because the four peptides have markedly different reported half-lives, a frequency that is appropriate for one component's kinetics will not be appropriate for all four simultaneously. ## BPC-157 dose context from the research literature In rodent tendon-repair studies, BPC-157 was administered at 10 μg, 10 ng or 10 pg per rat (intraperitoneal, once daily) in the Staresinic 2003 Achilles transection study [2]. The Krivic 2006 Achilles detachment study and the Cerovecki 2010 ligament study did not report specific dose values [9, 10]. Pharmacokintically, BPC-157 shows a very short elimination half-life (under 30 minutes in the formal 2022 PK study), intramuscular bioavailability of approximately 14–19% in rats and 45–51% in beagle dogs, and excretion via urine and bile [8]. The peptide breaks down into small fragments entering normal amino-acid metabolism. In the 2025 human IV safety pilot (n=2), BPC-157 was administered at 10 mg on day 1 and 20 mg on day 2, each in 250 cc saline as a 1-hour infusion [6]. That is a single-session safety observation, not a dosing protocol. A 2025 narrative review concluded that the dose-response literature remains almost entirely preclinical and that rigorous, large-scale human trials are lacking [13]. KLOW research note: BPC-157 contributes 10 mg to the canonical 80 mg vial — the same order of magnitude as the 2025 human pilot, though the route and vehicle differ. ## TB-500 dose context from the research literature Foundational efficacy data for the TB-500 arm derive from thymosin β4 (the full-length native protein, not the Ac-LKKTETQ fragment) studies. In the Malinda 1999 wound model, thymosin β4 was administered topically and intraperitoneally; as little as 10 pg stimulated keratinocyte migration 2–3-fold in migration assays [1]. The TB-500 fragment (Ac-LKKTETQ) has not undergone formal human pharmacokinetic characterization. It is distinct from full-length thymosin beta-4, and the dose ranges established for the native protein do not automatically transfer to the fragment. ## GHK-Cu dose context from the research literature In cell-culture validation for the gene-expression work, GHK-Cu showed activity at 1–10 nM [5]. In clinical topical studies, formulated creams and serums were used at concentrations not individually reported in the public literature; the skin-regeneration review documented clinical improvements at standard topical concentrations [4]. GHK-Cu contributes 50 mg to the canonical 80 mg KLOW vial — the mass-dominant component, about 62.5% by mass — with each molecule carrying a chelated copper(II) ion. For injectable research use, the copper load per vial is therefore substantially higher than in topical cosmetic applications. ## KPV dose context from the research literature In the Dalmasso 2008 mechanistic study, KPV was active at 10 nM in cell-culture (human intestinal epithelial cell lines and Jurkat T cells) and was administered at 100 μM in drinking water in the mouse colitis models [3]. The PepT1 transporter Km for KPV is approximately 160 μM. KPV contributes 10 mg to the canonical 80 mg KLOW vial. The route context matters: most KPV research was conducted in oral or cell-culture settings, not in the subcutaneous injectable context implied by research-vial use. The in vivo bioavailability and systemic exposure of injected KPV have not been formally characterized. ## Stability and compatibility notes KLOW is supplied as a lyophilized blend. Reconstituted solution is typically refrigerated for laboratory handling. A theoretical compatibility consideration: copper(II) in GHK-Cu can participate in redox chemistry when co-dissolved with the other three peptides in one vial. This has not been formally characterized for this mixture. The pharmacokinetic mismatch is inherent and worth stating plainly: BPC-157's elimination half-life under 30 minutes [8] means it clears far faster than GHK-Cu's reported activity profile. A single co-formulated dose cannot maintain all four components at matched tissue exposures — a structural limitation that has not been addressed by any published research. --- A single-hue reading room for the peer-reviewed component literature — four peptides, four separate evidence columns, and the untested blend column left in plain sight.